nach oben

Erschienen in:

01.05.2009 | Original Article

The combined evaluation of interim contrast-enhanced computerized tomography (CT) and FDG-PET/CT predicts the clinical outcomes and may impact on the therapeutic plans in patients with aggressive non-Hodgkin’s lymphoma

verfasst von: Deok-Hwan Yang, Jung-Joon Min, Yong Yeon Jeong, Jae-Sook Ahn, Yeo-Kyeoung Kim, Sang-Hee Cho, Ik-Joo Chung, Hee-Seung Bom, Hyeoung-Joon Kim, Je-Jung Lee

Erschienen in: Annals of Hematology | Ausgabe 5/2009

Einloggen, um Zugang zu erhalten

Abstract

We investigated the concomitant interim response of patients with aggressive non-Hodgkin’s lymphoma (NHL) using multi-detector row computerized tomography (CT) and ¹⁸F-fluoro-2-deoxy-d-glucose-positron emission tomography (PET)/CT for prediction of clinical outcomes. One hundred six newly diagnosed patients with aggressive NHL were enrolled. Both the CT and PET/CT were serially performed at the time of diagnosis and after three to four cycles of chemotherapy (interim). The patients were categorized into four different responsive groups according to the interim PET/CT and CT: (1) complete metabolic response (CMR)–complete response unconfirmed (CRu), (2) CMR–partial response (PR), (3) partial metabolic response (PMR)–Cru, and (4) PMR–PR. Fifty-five patients with CMR–CRu, 20 patients with CMR–PR, seven patients with PMR–Cru, and 23 patients with PMR–PR were distributed. In addition, one patient experienced a disease progression. There was a significant difference in relapse rates between PET/CT-positive (67.3%) and PET/CT-negative patients (17.3%; P < 0.01). Also, there was a significant difference between patients with PMR–PR (32.0% and 26.1%) and CMR–CRu (89.3% and 80.0%) for 3-year overall survival (OS) and event-free survival (EFS), respectively. A multivariate analysis revealed that high international prognostic index (≥3) at diagnosis, T-cell phenotype, and PMR–PR in interim PET/CT and CT were independent prognostic significances for OS. Moreover, bulky disease (>10 cm), T-cell phenotype, and PMR–PR showed significant associations for EFS. PMR–PR in interim response was the predictive prognostic determinant for both OS and EFS, with a hazard ratio of 3.93 (1.61–9.60) and 3.60 (1.62–7.98), respectively. The combined evaluation of interim PET/CT and CT was found to be a significant predictor of disease progression, OS, and EFS.

Spaepen K, Stroobants S, Dupont P, Van Steenweghen S, Thomas J, Vandenberghe P et al (2001) Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin’s lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 19:414–419PubMed

Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P et al (1999) Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin’s disease and non-Hodgkin’s lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 94:429–433PubMed

Mikhaeel NG, Timothy AR, O’Doherty MJ, Hain S, Maisey MN (2000) 18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin’s lymphoma—comparison with CT. Leuk Lymphoma 39:543–553PubMed

Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM et al (1999) Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244PubMed

Surbone A, Longo DL, DeVita VT Jr, Ihde DC, Duffey PL, Jaffe ES et al (1988) Residual abdominal masses in aggressive non-Hodgkin’s lymphoma after combination chemotherapy: significance and management. J Clin Oncol 6:1832–1837PubMed

Coiffier B, Gisselbrecht C, Herbrecht R, Tilly H, Bosly A, Brousse N (1989) LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J Clin Oncol 7:1018–1026PubMed

Canellos GP (1988) Residual mass in lymphoma may not be residual disease. J Clin Oncol 6:931–933PubMed

Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ (2002) PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin’s disease. J Nucl Med 43:1018–1027PubMed

Kostakoglu L (2002) Noninvasive detection of multidrug resistance in patients with hematological malignancies: are we there yet? Clin Lymphoma 2:242–248PubMedCrossRef

10.

Querellou S, Valette F, Bodet-Milin C, Oudoux A, Carlier T, Harousseau JL et al (2006) FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin’s lymphoma and Hodgkin’s disease. Ann Hematol 85:759–767 doi:10.1007/s00277-006-0151-z PubMedCrossRef

11.

Picardi M, De Renzo A, Pane F, Nicolai E, Pacelli R, Salvatore M et al (2007) Randomized comparison of consolidation radiation versus observation in bulky Hodgkin’s lymphoma with post-chemotherapy negative positron emission tomography scans. Leuk Lymphoma 48:1721–1727 doi:10.1080/10428190701559140 PubMedCrossRef

12.

Zhao J, Qiao W, Wang C, Wang T, Xing Y (2007) Therapeutic evaluation and prognostic value of interim hybrid PET/CT with (18)F-FDG after three to four cycles of chemotherapy in non-Hodgkin’s lymphoma. Hematology 12(5):423–430PubMedCrossRef

13.

Fields PA, Mikhaeel G, Hutchings M, van der Walt J, Nunan T, Schey SA (2005) The prognostic value of interim positron emission tomography scans combined with immunohistochemical data in diffuse large B-cell lymphoma. Haematologica 90:1711–1713PubMed

14.

(1993) A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med 329:987–994. doi:10.1056/NEJM199309303291402

15.

Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI et al (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346:1937–1947 doi:10.1056/NEJMoa012914 PubMedCrossRef

16.

Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P et al (2007) The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109:1857–1861 doi:10.1182/blood-2006-08-038257 PubMedCrossRef

17.

Armitage JO, Weisenburger DD, Hutchins M, Moravec DF, Dowling M, Sorensen S et al (1986) Chemotherapy for diffuse large-cell lymphoma—rapidly responding patients have more durable remissions. J Clin Oncol 4:160–164PubMed

18.

Rodriguez-Catarino M, Jerkeman M, Ahlstrom H, Glimelius B, Hagberg H (2000) Residual mass in aggressive lymphoma–does size, measured by computed tomography, influence clinical outcome? Acta Oncol 39:485–489 doi:10.1080/028418600750013393 PubMedCrossRef

19.

Haioun C, Itti E, Rahmouni A, Brice P, Rain JD, Belhadj K et al (2005) [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 106:1376–1381 doi:10.1182/blood-2005-01-0272 PubMedCrossRef

20.

Mikhaeel NG, Hutchings M, Fields PA, O’Doherty MJ, Timothy AR (2005) FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 16:1514–1523 doi:10.1093/annonc/mdi272 PubMedCrossRef

21.

Hutchings M, Mikhaeel NG, Fields PA, Nunan T, Timothy AR (2005) Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 16:1160–1168 doi:10.1093/annonc/mdi200 PubMedCrossRef

22.

Hutchings M, Loft A, Hansen M, Pedersen LM, Buhl T, Jurlander J et al (2006) FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107:52–59 doi:10.1182/blood-2005-06-2252 PubMedCrossRef

23.

Lapela M, Leskinen S, Minn HR, Lindholm P, Klemi PJ, Soderstrom KO et al (1995) Increased glucose metabolism in untreated non-Hodgkin’s lymphoma: a study with positron emission tomography and fluorine-18-fluorodeoxyglucose. Blood 86:3522–3527PubMed

24.

Schoder H, Noy A, Gonen M, Weng L, Green D, Erdi YE et al (2005) Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin’s lymphoma. J Clin Oncol 23:4643–4651 doi:10.1200/JCO.2005.12.072 PubMedCrossRef

25.

Reinhardt MJ, Herkel C, Altehoefer C, Finke J, Moser E (2005) Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin’s and non-Hodgkin’s lymphoma patients: when do we really need FDG-PET? Ann Oncol 16:1524–1529 doi:10.1093/annonc/mdi271 PubMedCrossRef

26.

Castellucci P, Nanni C, Farsad M, Alinari L, Zinzani P, Stefoni V et al (2005) Potential pitfalls of 18F-FDG PET in a large series of patients treated for malignant lymphoma: prevalence and scan interpretation. Nucl Med Commun 26:689–694 doi:10.1097/01.mnm.0000171781.11027.bb PubMedCrossRef

27.

Schoder H, Moskowitz C (2008) PET imaging for response assessment in lymphoma: potential and limitations. Radiol Clin North Am 46:225–241 doi:10.1016/j.rcl.2008.04.002 PubMedCrossRef

Titel: The combined evaluation of interim contrast-enhanced computerized tomography (CT) and FDG-PET/CT predicts the clinical outcomes and may impact on the therapeutic plans in patients with aggressive non-Hodgkin’s lymphoma
verfasst von: Deok-Hwan Yang
Jung-Joon Min
Yong Yeon Jeong
Jae-Sook Ahn
Yeo-Kyeoung Kim
Sang-Hee Cho
Ik-Joo Chung
Hee-Seung Bom
Hyeoung-Joon Kim
Je-Jung Lee
Publikationsdatum: 01.05.2009
Verlag: Springer-Verlag
Erschienen in: Annals of Hematology / Ausgabe 5/2009
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-008-0616-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2009

A case of primary MALT lymphoma of the endometrium presenting as an asymptomatic polyp

Treatment of primary mediastinal large B cell lymphoma with an alternating chemotherapy regimen based on high-dose methotrexate

Primary localized stages I and II non-Hodgkin’s lymphoma of the nasopharynx: a retrospective 17-year single institutional experience

EBV-negative Hodgkin lymphoma in ZAP-70-positive B-cell lymphocytic leukemia patient

Comparison of whole-body MR imaging and conventional X-ray examination in patients with multiple myeloma and implications for therapy

Impact of 789Ala/Ala genotype on quantitative type of von Willebrand disease